IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling

Hyung-Mun Yun1, Kyung-Ran Park1, Eun-Cheol Kim1

  • 1Department of Maxillofacial Tissue Regeneration, School of Dentistry and Research Center for Tooth & Periodontal Regeneration (MRC), Kyung Hee University, Seoul 130-701, Republic of Korea.

Oncotarget
|April 25, 2015
PubMed

Insights

Interleukin-32 alpha (IL-32α) suppresses colon cancer by enhancing tumor cell death signaling. This finding suggests IL-32α could be a therapeutic target for inflammation-linked colorectal cancer.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Inflammation creates a microenvironment conducive to cancer development.
  • Interleukin-32 (IL-32) is implicated in human cancers associated with chronic inflammation.

Purpose of the Study:

  • To investigate the role of Interleukin-32 alpha (IL-32α) in inflammation-driven colorectal carcinogenesis.
  • To elucidate the mechanisms by which IL-32α influences colon cancer development.

Main Methods:

  • Generation of a transgenic mouse model expressing IL-32α (IL-32α-Tg).
  • Induction of colon cancer in mice using azoxymethane (AOM).
  • Analysis of tumor incidence, TNFR1 expression, apoptosis, reactive oxygen species (ROS) production, and JNK activation.

Main Results:

  • IL-32α transgenic mice exhibited decreased AOM-induced colon cancer incidence.
  • Expression of TNFR1 and TNFR1-mediated apoptosis were increased in IL-32α-Tg mice.
  • IL-32α elevated ROS production, leading to sustained JNK activation, and was found to be upregulated in human colon cancer patients alongside TNFR1.

Conclusions:

  • IL-32α suppresses colon cancer development.
  • This suppression is mediated by promoting TNFR1-dependent apoptosis signaling.
  • IL-32α may represent a novel therapeutic target for colorectal cancer prevention and treatment.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
802
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.4K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.8K